Nanhua Bio (China) Performance
| 000504 Stock | 10.42 0.15 1.46% |
On a scale of 0 to 100, Nanhua Bio holds a performance score of 11. The company secures a Beta (Market Risk) of 0.16, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Nanhua Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Nanhua Bio is expected to be smaller as well. Please check Nanhua Bio's semi deviation, coefficient of variation, jensen alpha, as well as the relationship between the downside deviation and standard deviation , to make a quick decision on whether Nanhua Bio's current price movements will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Nanhua Bio Medicine are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Nanhua Bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 218.1 M | |
| Free Cash Flow | 30.4 M |
Nanhua |
Nanhua Bio Relative Risk vs. Return Landscape
If you would invest 765.00 in Nanhua Bio Medicine on August 31, 2024 and sell it today you would earn a total of 277.00 from holding Nanhua Bio Medicine or generate 36.21% return on investment over 90 days. Nanhua Bio Medicine is generating 0.6223% of daily returns and assumes 4.2609% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than Nanhua, and 88% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nanhua Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nanhua Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nanhua Bio Medicine, and traders can use it to determine the average amount a Nanhua Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.146
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 000504 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.26 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Nanhua Bio is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nanhua Bio by adding it to a well-diversified portfolio.
Nanhua Bio Fundamentals Growth
Nanhua Stock prices reflect investors' perceptions of the future prospects and financial health of Nanhua Bio, and Nanhua Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nanhua Stock performance.
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0455 | |||
| Profit Margin | (0.30) % | |||
| Operating Margin | 0.01 % | |||
| Current Valuation | 3.1 B | |||
| Shares Outstanding | 330.02 M | |||
| Price To Book | 13.63 X | |||
| Price To Sales | 27.34 X | |||
| Revenue | 136.79 M | |||
| EBITDA | (38.19 M) | |||
| Total Debt | 28.12 M | |||
| Book Value Per Share | 0.75 X | |||
| Cash Flow From Operations | 36.28 M | |||
| Earnings Per Share | (0.12) X | |||
| Total Asset | 771.38 M | |||
| Retained Earnings | (531.1 M) | |||
About Nanhua Bio Performance
By analyzing Nanhua Bio's fundamental ratios, stakeholders can gain valuable insights into Nanhua Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nanhua Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nanhua Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Nanhua Bio Medicine performance evaluation
Checking the ongoing alerts about Nanhua Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nanhua Bio Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nanhua Bio Medicine appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 136.79 M. Net Loss for the year was (28.17 M) with profit before overhead, payroll, taxes, and interest of 127.36 M. | |
| About 13.0% of the company shares are owned by insiders or employees |
- Analyzing Nanhua Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nanhua Bio's stock is overvalued or undervalued compared to its peers.
- Examining Nanhua Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nanhua Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nanhua Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nanhua Bio's stock. These opinions can provide insight into Nanhua Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nanhua Stock analysis
When running Nanhua Bio's price analysis, check to measure Nanhua Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanhua Bio is operating at the current time. Most of Nanhua Bio's value examination focuses on studying past and present price action to predict the probability of Nanhua Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanhua Bio's price. Additionally, you may evaluate how the addition of Nanhua Bio to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |